Durvalumab and Oleclumab in Resectable PDAC (DORA)

Durvalumab and Oleclumab in Resectable PDAC: A Window of Opportunity Study (DORA Trial)

This is a multi-site Canadian, window of opportunity study to evaluate the immune activity of durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma (PDAC) when given prior to surgery.

Study Overview

• Status: Recruiting
• Conditions: Pancreatic Ductal Adenocarcinoma
• Intervention / Treatment: Drug: Durvalumab; Drug: Oleclumab

• Study Type: Interventional
• Enrollment (Estimated): 22
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Malcolm Moore, MD; Phone Number: 416-946-2263; Email: malcolm.moore@uhn.ca

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M5G 2M9
      • Recruiting
      • Princess Margaret Cancer Centre
      • Contact: Malcolm Moore, MD
      • Principal Investigator: Malcolm Moore, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Weight ≥ 35 kg
• Have a life expectancy ≥ 12 weeks
• Have histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC).
• Upfront resectable PDAC
• Have adequate organ and marrow function required for the study
• Baseline images taken prior to treatment must undergo central review
• Participants must agree to use study approved methods to prevent pregnancy for study required period

Exclusion Criteria:

• Receipt of any conventional or investigational anticancer therapy within 21 days or palliative radiotherapy within 14 days prior to the scheduled first dose of study treatment
• Prior receipt of any immune-mediated therapy including, but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1 including durvalumab antibodies and agents targeting CD73, CD39, or adenosine receptors, excluding therapeutic anticancer vaccines.
• Concurrent enrolment in another therapeutic clinical study. Enrolment in observational studies will be allowed.
• Have a history of Grade 3 or greater thromboembolic events in the prior 3 months or thromboembolic event of any grade with ongoing symptoms.
• Have prior history of myocardial infarction, transient ischemic attack, congestive heart failure ≥ Class 3 based on New York Heart Association Functional Classification or stroke within the past 3 months prior to the scheduled first dose of study treatment.

• Active or prior documented autoimmune disorders within the past 3 years prior to the scheduled first dose of study treatment with the following exceptions

  • Vitiligo or alopecia
  • Hypothyroidism not requiring systemic treatment or stable on hormone replacement
  • Psoriasis not requiring systemic treatment
  • Any chronic skin condition that does not require systemic therapy
• Have known active hepatitis infection. Participants with a past or resolved Hepatitis B (HBV) infection are eligible. Participants positive for Hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
• Known to have tested positive for human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies) or active tuberculosis infection
• Other invasive malignancy within 5 years.
• Known allergy or hypersensitivity to investigational product formulations.
• Active grade 3 or greater edema
• Uncontrolled intercurrent illness

• Current or prior use of immunosuppressive medication within 14 days prior to the scheduled first dose of study treatment with the following exceptions:

  • Intranasal, topical, inhaled corticosteroids or local steroid injections
  • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent
  • Steroids as premedication for hypersensitivity reaction
• Receipt of live, attenuated vaccine within 30 days prior to the scheduled first dose of study treatment
• Major surgery within 28 days prior to scheduled first dose of study treatment or still recovering from prior surgery. Local are allowed, without needing to wait for the 28 day recovery period.
• Are pregnant, lactating, or intend to become pregnant during their participation in the study
• Any condition that, in the opinion of the investigator, would interfere with safe administration or evaluation of the investigational products or interpretation of subject safety or study results

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Durvalumab and Oleclumab; Durvalumab, 1500 mg x 1 dose and oleclumab 3000 mg x 2 doses every 2 weeks prior to surgical resection.	Drug: Durvalumab; Durvalumab is a monoclonal antibody that blocks the interaction of PD-L1 with PD-1 on immune cells.; Other Names: IMFINZI; Drug: Oleclumab; Oleclumab is a monoclonal antibody that binds to and inhibits the activity of CD73.; Other Names: MEDI9447

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Percent change in CD8+ cell infiltration	Baseline biopsy to surgical resection (35 days)

Secondary Outcome Measures

Outcome Measure	Time Frame
Percent change in CD3 cell population in tumour tissue	Baseline biopsy to surgical resection (35 days)
Percent change in CD3 cell population in blood	Baseline biopsy to surgical resection (35 days)
Percent change in CD45RA cell population in tumour tissue	Baseline biopsy to surgical resection (35 days)
Percent change in CD45RA cell population in blood	Baseline biopsy to surgical resection (35 days)
Percent change in RO T cell population in tumour tissue	Baseline biopsy to surgical resection (35 days)
Percent change in RO T cell population in blood	Baseline biopsy to surgical resection (35 days)
Percent change in M1 vs M2 macrophage population in tumour tissue	Baseline biopsy to surgical resection (35 days)
Percent change in M1 vs M2 macrophage population in blood	Baseline biopsy to surgical resection (35 days)

Collaborators and Investigators

• Sponsor: University Health Network, Toronto
• Investigators: Principal Investigator: Malcolm Moore, MD, Princess Margaret Cancer Centre/University Health Network

Study record dates

Study Major Dates

• Study Start (Actual): November 29, 2023
• Primary Completion (Estimated): October 30, 2026
• Study Completion (Estimated): October 30, 2026

Study Registration Dates

• First Submitted: September 22, 2023
• First Submitted That Met QC Criteria: September 22, 2023
• First Posted (Actual): September 29, 2023

Study Record Updates

• Last Update Posted (Estimated): January 8, 2024
• Last Update Submitted That Met QC Criteria: January 5, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Carcinoma; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Immunological; Durvalumab
• Other Study ID Numbers: OZUHN-013; 22-6031 (Other Identifier: University Health Network)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No